implications of the ictan trial of icotinib for resected egfr-mutated stage ii-iiia nsclc
Published 3 months ago • 84 plays • Length 0:50Download video MP4
Download video MP3
Similar videos
-
1:07
insights into a phase iii trial of icotinib for resected egfr-mutated stage ii-iiia nsclc
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
0:43
developments in the management of egfr-mutated nsclc
-
1:46
osimertinib after surgery significantly improves survival in resected egfr-mutated nsclc
-
1:24
dr. halmos on the implications of the ipass study in lung cancer
-
4:55
practical implications of the relay trial in egfr nsclc
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
1:51
evaluating first-line therapies for egfr-mutated nsclc in 2024
-
0:55
flowers: osimertinib and savolitinib in met aberrant, egfrm nsclc
-
3:13
updates from adaura: continued dfs benefit with osimertinib vs. placebo
-
3:52
is adjuvant chemotherapy in egfr mutated nsclc still required?
-
1:50
consolidation therapy for unresectable stage iii egfr-mutant nsclc
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
1:29
dr. bertino on the impact of the egfr-mutated subset analysis of impower150 in nsclc
-
2:47
etop clinical trials in egfr-, krasg12c- and alk-mutated nsclc
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc